Hetero launches fixed dose combination drug for HIV in India

Published On 2018-02-28 05:00 GMT   |   Update On 2018-02-28 05:00 GMT

New Delhi: Drug firm Hetero said it has launched generic anti-retroviral fixed-dose combination (FDC) of Emtricitabine (200mg) and Tenofovir Alafenamide (25mg) in India.


The product has been approved by Drug Controller General of India (DCGI)) and will be marketed and distributed under the brand name 'TAFERO-EM' by Hetero Healthcare Ltd, the company said in a statement.


The FDC drug is an anti-retroviral medication which is indicated in combination with other anti-retroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adults and pediatric patients 12 years of age and older, it added.


The company's FDC product "is the first generic version of Gilead s Descovy," Hetero said.


With more than 200 products in its portfolio across various therapeutic areas, Hetero currently has the presence in over 120 countries.

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News